妊娠期发生不典型溶血性尿毒症综合征1例报告

E. Smirnova, Ol'ga V. Kurtikova
{"title":"妊娠期发生不典型溶血性尿毒症综合征1例报告","authors":"E. Smirnova, Ol'ga V. Kurtikova","doi":"10.17816/pavlovj106407","DOIUrl":null,"url":null,"abstract":"Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare (orphan) disease with a progressive course, which is a systemic thrombotic microangiopathy resulting from uncontrolled activation of the alternative complement pathway. There exist the so called obstetric thombotic microangiopathies (pre-eclampsia, HELLP syndrome) which are considered as triggers causing development of aHUS in pregnancy in genetically predisposed female patients. Here, the main peculiarity of these pathologies is the improvement of the condition of the puerpera after delivery. In case of non-obstetric thombotic microangiopathies, delivery does not lead to regress of symptoms, on the contrary, microangiopathic process progresses with rapid development of multiorgan failure. The development of thrombotic thrombocytopenic purpura and aHUS in pregnancy may induce physiological changes in the organism of a pregnant woman. There occurs a build-up of the activity of von Willebrand factor with a parallel reduction of the activity of ADAMTS 13 enzyme (metalloprotease that cleaves its super-large multimers). This is probably a physiological adaptation of the body to minimize blood loss during childbirth. As a result of the imbalance, the risk of developing thrombotic microangiopathy increases by the end of II beginning of III trimester. The concept of chronic uncontrolled activation of the alternative complement pathway implies a genetic defect of regulatory proteins with increased formation of C5 convertase, increased release of C5a a strong chemoattractant, and of membraneattacking complex C5bC9, which leads to damage to endothelial cells, exposure of the subendothelial layer and thrombosis. The currently used drug eculizumab is a recombinant humanized monoclonal antibody that binds to the complement C5 protein and suppresses the activation of complement-mediated cell lysis. The article presents a clinical case of the development of aHUS in a patient during pregnancy, the main stages of diagnostic search are considered, routing is determined and the therapy used is justified.","PeriodicalId":113364,"journal":{"name":"I.P. Pavlov Russian Medical Biological Herald","volume":"57 10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Report of Development of Atypical Hemolytic-Uremic Syndrome in Pregnancy\",\"authors\":\"E. Smirnova, Ol'ga V. Kurtikova\",\"doi\":\"10.17816/pavlovj106407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare (orphan) disease with a progressive course, which is a systemic thrombotic microangiopathy resulting from uncontrolled activation of the alternative complement pathway. There exist the so called obstetric thombotic microangiopathies (pre-eclampsia, HELLP syndrome) which are considered as triggers causing development of aHUS in pregnancy in genetically predisposed female patients. Here, the main peculiarity of these pathologies is the improvement of the condition of the puerpera after delivery. In case of non-obstetric thombotic microangiopathies, delivery does not lead to regress of symptoms, on the contrary, microangiopathic process progresses with rapid development of multiorgan failure. The development of thrombotic thrombocytopenic purpura and aHUS in pregnancy may induce physiological changes in the organism of a pregnant woman. There occurs a build-up of the activity of von Willebrand factor with a parallel reduction of the activity of ADAMTS 13 enzyme (metalloprotease that cleaves its super-large multimers). This is probably a physiological adaptation of the body to minimize blood loss during childbirth. As a result of the imbalance, the risk of developing thrombotic microangiopathy increases by the end of II beginning of III trimester. The concept of chronic uncontrolled activation of the alternative complement pathway implies a genetic defect of regulatory proteins with increased formation of C5 convertase, increased release of C5a a strong chemoattractant, and of membraneattacking complex C5bC9, which leads to damage to endothelial cells, exposure of the subendothelial layer and thrombosis. The currently used drug eculizumab is a recombinant humanized monoclonal antibody that binds to the complement C5 protein and suppresses the activation of complement-mediated cell lysis. The article presents a clinical case of the development of aHUS in a patient during pregnancy, the main stages of diagnostic search are considered, routing is determined and the therapy used is justified.\",\"PeriodicalId\":113364,\"journal\":{\"name\":\"I.P. Pavlov Russian Medical Biological Herald\",\"volume\":\"57 10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"I.P. Pavlov Russian Medical Biological Herald\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17816/pavlovj106407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"I.P. Pavlov Russian Medical Biological Herald","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/pavlovj106407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

非典型溶血性尿毒症综合征(aHUS)是一种具有进行性病程的超罕见(孤儿)疾病,是一种由替代补体途径不受控制的激活引起的系统性血栓性微血管病变。存在所谓的产科血栓性微血管病变(先兆子痫,HELLP综合征),这被认为是在遗传易感的女性患者怀孕期间导致aHUS发展的触发因素。在这里,这些病理的主要特点是分娩后产妇状况的改善。对于非产科血栓性微血管病变,分娩并不会导致症状的消退,相反,微血管病变过程会随着多器官功能衰竭的快速发展而进展。血栓性血小板减少性紫癜和妊娠期aHUS的发展可能会引起孕妇机体的生理变化。血管性血友病因子的活性随着ADAMTS - 13酶(切割其超大多聚体的金属蛋白酶)活性的平行降低而增加。这可能是身体的一种生理适应,以尽量减少分娩时的失血。由于这种不平衡,发展成血栓性微血管病的风险在妊娠末期和妊娠初期增加。替代补体途径的慢性不受控制激活的概念意味着调节蛋白的遗传缺陷,C5转化酶的形成增加,C5a(强化学引诱剂)的释放增加,以及膜攻击复合物C5bC9的释放增加,导致内皮细胞损伤,内皮下层暴露和血栓形成。目前使用的药物eculizumab是一种重组人源化单克隆抗体,与补体C5蛋白结合,抑制补体介导的细胞裂解的激活。本文介绍了一个临床病例的发展aHUS患者在怀孕期间,诊断搜索的主要阶段是考虑,路线确定和使用的治疗是合理的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Case Report of Development of Atypical Hemolytic-Uremic Syndrome in Pregnancy
Atypical hemolytic-uremic syndrome (aHUS) is an ultra-rare (orphan) disease with a progressive course, which is a systemic thrombotic microangiopathy resulting from uncontrolled activation of the alternative complement pathway. There exist the so called obstetric thombotic microangiopathies (pre-eclampsia, HELLP syndrome) which are considered as triggers causing development of aHUS in pregnancy in genetically predisposed female patients. Here, the main peculiarity of these pathologies is the improvement of the condition of the puerpera after delivery. In case of non-obstetric thombotic microangiopathies, delivery does not lead to regress of symptoms, on the contrary, microangiopathic process progresses with rapid development of multiorgan failure. The development of thrombotic thrombocytopenic purpura and aHUS in pregnancy may induce physiological changes in the organism of a pregnant woman. There occurs a build-up of the activity of von Willebrand factor with a parallel reduction of the activity of ADAMTS 13 enzyme (metalloprotease that cleaves its super-large multimers). This is probably a physiological adaptation of the body to minimize blood loss during childbirth. As a result of the imbalance, the risk of developing thrombotic microangiopathy increases by the end of II beginning of III trimester. The concept of chronic uncontrolled activation of the alternative complement pathway implies a genetic defect of regulatory proteins with increased formation of C5 convertase, increased release of C5a a strong chemoattractant, and of membraneattacking complex C5bC9, which leads to damage to endothelial cells, exposure of the subendothelial layer and thrombosis. The currently used drug eculizumab is a recombinant humanized monoclonal antibody that binds to the complement C5 protein and suppresses the activation of complement-mediated cell lysis. The article presents a clinical case of the development of aHUS in a patient during pregnancy, the main stages of diagnostic search are considered, routing is determined and the therapy used is justified.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
0
期刊最新文献
Comparative Evaluation of Effectiveness of Lesser Toe Surgical Correction Routine Coronary Angiography and Functional Cardiac Tests before Resection of Abdominal Aortic Aneurysm in Patients without Symptoms of Myocardial Infarction Elimination of Intestinal Hypoxia in Complex Treatment of Intestinal Failure (Case Report) Clinical Case of a Foreign Body in the Soft Tissues surrounding the Knee Joint: to Help the Practitione Breast Cancer Resistance Protein: Structure, Localization, Functions, Significance for Rational Pharmacotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1